Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 06, 2023, titled "Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics".